LLY·Healthcare·Pharma
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite?
Healthcare
LLY·Healthcare·Pharma
JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?
CLOV·Healthcare·Meme Stocks
Clover Health Star Rating Jumps After 4.5-Star CMS Upgrade
Did CMS just hand Clover Health the kind of rating upgrade that can change its growth story overnight?
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s…
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1…
MDT·Healthcare·Dividend Aristocrats
Medtronic Upgrade Sends Shares Up 5.1% After Q2 Beat
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike?
LLY·Healthcare·Pharma
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy?
UNH·Healthcare
UnitedHealth Upgrade +5.9% After Bank of America Buy Call
Can a fresh Wall Street buy call finally reset the narrative around UnitedHealth after months of Medicare pressure?
NVO·Healthcare·Pharma
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum?
LLY·Healthcare·Pharma
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war?